Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2001-06-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.141226398PMID 11427731PMCID PMC37517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.

  2011cited by this paper
• Dendritic cells in cancer immunotherapy.

  2000cited by this paper
• Agonist peptide from a cytotoxic t‐lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1‐type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide

  2000cited by this paper
• Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids

  2000cited by this paper
• Immunobiology of dendritic cells.

  2000cited by this paper
• In vivo generation of human dendritic cell subsets by Flt3 ligand

  2000cited by this paper
• In vivo generation of human dendritic cell subsets by Flt3 ligand.

  2000cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

  1999cited by this paper
• Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division.

  1999cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

  1999cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• CD45RA(bright)/CD11a(bright) CD8+ T cells: effector T cells.

  1998cited by this paper
• Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues.

  1998cited by this paper
• c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities.

  1998cited by this paper
• Role of carcinoembryonic antigen in the management of advanced colorectal cancer.

  1998cited by this paper
• Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

  1998cited by this paper
• Dose intensity in small cell lung cancer.

  1998cited by this paper
• Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.

  1997cited by this paper
• Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.

  1997cited by this paper
• Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells

  1997cited by this paper
• Effects of Epitope Modification on T Cell Receptor–Ligand Binding and Antigen Recognition by Seven H-2Kd–restricted Cytotoxic T Lymphocyte Clones Specific for a Photoreactive Peptide Derivative

  1997cited by this paper
• Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

  1996cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

  1996cited by this paper
• Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts

  1996cited by this paper
• CD8highCD57+ T lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus.

  1995cited by this paper
• A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex

  1995cited by this paper
• Positive selection of thymocytes.

  1995cited by this paper
• Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.

  1995cited by this paper
• CD28- T lymphocytes. Antigenic and functional properties.

  1993cited by this paper
• Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

  1992cited by this paper

• Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities

  2025cites this paper
• Leveraging T cells for cancer immunotherapy

  2025cites this paper
• DNGR-1 regulates proliferation and migration of bone marrow dendritic cell progenitors

  2025influential citation
• Recent research progress and clinical status of immunotherapy for colorectal cancer.

  2025cites this paper
• The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles

  2025cites this paper
• Revitalizing systemic immune responses in advanced NSCLC using FLT3L and SBRT

  2025cites this paper
• Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer

  2025cites this paper
• Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches

  2025cites this paper
• Colorectal Cancer Spectrum: From Subtypes and Epidemiology to Oncotherapies

  2025cites this paper
• A Review on Colorectal Cancer and the Role of Traditional Chinese Herbal Medicine as Complementary Therapy

  2024cites this paper
• The current therapeutic cancer vaccines landscape in non‐small cell lung cancer

  2024cites this paper
• FLT3L-induced virtual memory CD8 T cells engage the immune system against tumors

  2024cites this paper
• BCG immunotherapy promotes tumor-derived T-cell activation through the FLT3/FLT3LG pathway in bladder cancer

  2024cites this paper
• Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets.

  2024cites this paper
• Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

  2024cites this paper
• Immunotherapy for colorectal cancer

  2024cites this paper
• Nanomedicine in cancer treatment - an overview

  2024cites this paper
• Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review

  2024cites this paper
• Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy

  2024cites this paper
• Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

  2023cites this paper
• Multiple Protein Biomarkers and Different Treatment Strategies for Colorectal Carcinoma: A Comprehensive Prospective.

  2023cites this paper
• Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer

  2023cites this paper
• Colorectal Cancer Immunotherapy: State of the Art and Future Directions

  2023cites this paper
• Novel bioengineering strategies for drug delivery systems.

  2023cites this paper
• CEA vaccines

  2023cites this paper
• The Tolerogenic Influence of Dexamethasone on Dendritic Cells Is Accompanied by the Induction of Efferocytosis, Promoted by MERTK

  2023cites this paper
• Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

  2022cites this paper
• Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

  2022cites this paper
• Potential association factors for developing effective peptide-based cancer vaccines

  2022cites this paper
• Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies

  2022cites this paper
• Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors

  2022cites this paper
• Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer

  2022cites this paper
• Immunotherapies catering to the unmet medical need of cold colorectal cancer

  2022cites this paper
• Adoptive cell therapies in thoracic malignancies

  2022cites this paper
• DCision-making in tumors governs T cell anti-tumor immunity

  2021cites this paper
• Current status and future trends of vaccine development against viral infection and disease

  2021cites this paper
• Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.

  2021cites this paper
• Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

  2021cites this paper
• The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy

  2021influential citation
• New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy

  2021cites this paper
• Amplifying antitumor T cell immunity with versatile drug delivery systems for personalized cancer immunotherapy

  2021cites this paper
• Cancer Immunotherapy Strategies: Basic Principles

  2021cites this paper
• Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential

  2021cites this paper
• Dendritic Cell-Based Immunotherapy in Lung Cancer

  2021cites this paper
• DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

  2021cites this paper
• Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer

  2021cites this paper
• Unboxing dendritic cells: Tales of multi‐faceted biology and function

  2021cites this paper
• Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients

  2021cites this paper
• In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma

  2021cites this paper
• Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer

  2020cites this paper
• Therapeutic Vaccines for Gastrointestinal Malignancies

  2020cites this paper
• Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

  2020cites this paper
• Tumor Control, Elimination, and Escape through a Compartmental Model of Dendritic Cell Therapy for Melanoma

  2020cites this paper
• The clonal and molecular aetiology of emergency dendritic cell development

  2020cites this paper
• DENDRITIC CELL VACCINE THERAPY FOR COLORECTAL CANCER.

  2020cites this paper
• Increased M1 Macrophages Infiltration Correlated With Poor Survival Outcomes and Radiation Response in Gliomas

  2020cites this paper
• Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment

  2019cites this paper
• Peptide-based materials for cancer immunotherapy

  2019cites this paper
• UNIVERSITY OF SZEGED FACULTY OF MEDICINE EDIT OLASZ M.D. PRESENTATION OF SOLUBLE ANTIGENS AND HAPTENS BY MURINE BONE MARROW-DERIVED DENDRITIC CELLS-IMPLICATIONS FOR IMMUNOTHERAPY

  2019cites this paper
• Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies

  2019cites this paper
• The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis

  2019cites this paper
• Ex vivo dendritic cell generation-A critical comparison of current approaches.

  2019cites this paper
• New interpretable machine learning method for 1 single-cell data reveals correlates of clinical response to 2 cancer immunotherapy

  2019cites this paper
• A new data-driven cell population discovery and annotation method for single-cell data, FAUST, reveals correlates of clinical response to cancer immunotherapy

  2019cites this paper
• MAGE 3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer

  2018cites this paper
• Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis

  2018influential citation
• MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer.

  2018cites this paper
• Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity

  2018cites this paper
• Current Options and Future Directions in Immune Therapy for Glioblastoma

  2018cites this paper
• A new cancer immunotherapy via simultaneous DC‐mobilization and DC‐targeted IDO gene silencing using an immune‐stimulatory nanosystem

  2018cites this paper
• Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression

  2018cites this paper
• Updates on immunotherapy for colorectal cancer.

  2018cites this paper
• Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens

  2018cites this paper
• Immunotherapy in colon cancer: approaching to the future

  2018cites this paper
• Local Immunotherapies of Cancer

  2018cites this paper
• Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding.

  2018cites this paper
• Novel targeting approaches and signaling pathways of colorectal cancer: An insight

  2018cites this paper
• Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

  2018cites this paper
• 13 – Cancer Vaccines

  2018cites this paper
• DERVED FROM SURVIVIN

  2017cites this paper
• Dendritic Cell-Based Cancer Therapies: Current Status and Future Directions

  2017cites this paper
• Humanized Mice as Models to study Human Innate Immunity and Immunotherapies

  2017cites this paper
• Dendritic cell based vaccination strategy: an evolving paradigm

  2017cites this paper
• The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis

  2017cites this paper
• Cell Based Therapy: Modified Cancer Cells

  2017cites this paper
• 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.

  2017cites this paper
• Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes

  2016influential citation
• Novel avenues in immunotherapies for colorectal cancer

  2016cites this paper
• Personalized immunotherapy in colorectal cancer

  2016cites this paper
• The emerging role of immunotherapy in colorectal cancer.

  2016cites this paper
• Polymorphism in liver-stage malaria vaccine candidate proteins: immune evasion and implications for vaccine design

  2016cites this paper
• T-cell epitope mapping for the design of powerful vaccines

  2016cites this paper
• Dendritic Cell Vaccines.

  2016cites this paper
• Novel vaccines for glioblastoma: clinical update and perspective.

  2016cites this paper
• Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes Running Title: Anti-CEA DNA Fusion Vaccination

  2016influential citation
• FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines.

  2016cites this paper
• Dendritic cell-based cancer immunotherapy for colorectal cancer.

  2016cites this paper
• [Dendritic cell-based therapeutic cancer vaccines].

  2016cites this paper
• Prion diseases: immunotargets and therapy

  2016cites this paper
• Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes

  2016cites this paper